During the past decade, CHU Ambroise Paré conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 24 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 15 clinical trials were completed. i.e. 115.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Ambroise Paré" #1 sponsor was "European Lung Cancer Working Party" with 8 trials, followed by "Jules Bordet Institute" with 8 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Pfizer" with 4 trials sponsored and "Celgene" with 4 trials sponsored. Other sponsors include 44 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Ambroise Paré" #1 collaborator was "Erasme University Hospital" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "AGO Study Group" with 1 trials as a collaborator and "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator. Other collaborators include 72 different institutions and companies that were collaborators in the rest 82 trials.

According to Clinical.Site data, the most researched conditions in "CHU Ambroise Paré" are "Breast Cancer" (5 trials), "Multiple Myeloma" (3 trials), "Non Small Cell Lung Carcinoma" (3 trials), "Rheumatoid Arthritis" (3 trials) and "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "CHU Ambroise Paré" in a lesser frequency.

Most popular intervention types in "CHU Ambroise Paré" are "Drug" (63 trials), "Other" (9 trials), "Biological" (5 trials), "Device" (4 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Paclitaxel" (6 trials), "placebo" (4 trials), "Atezolizumab" (3 trials) and "Carboplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "CHU Ambroise Paré" are 64 trials for "All" genders, 11 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "CHU Ambroise Paré". undefined are not yet recruiting, 12 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in CHU Ambroise Paré, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Ambroise Paré, 1 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".